Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients With Irritable Bowel Syndrome With Constipation

NCT00215566 is registered in ClinicalTrials.gov with Dynogen Pharmaceuticals as lead sponsor.

NCT NCT00215566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00215566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients With Irritable Bowel Syndrome With Constipation
Lead sponsor
Dynogen Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
Not reported
Enrollment
90
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome, irritable bowel syndrome with constipation